The SCORE model in the POWER study: An attempt to focus the limited resources for prevention on patients with greatest need

Current Medical Research and Opinion, Supplement

Volumn 23, Issue 5, 2007, Pages

  De Backer, Guy ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

Cardiovascular (CV) risk; Cardiovascular disease (CVD); Coronary heart disease (CHD); POWER study; SCORE; Third joint task force

Indexed keywords

CARDIOVASCULAR RISK; CLINICAL PRACTICE; CONFERENCE PAPER; HEALTH CARE NEED; HEART PROTECTION; HUMAN; MEDICAL DECISION MAKING; MODEL; SYSTEMIC CORONARY RISK EVALUATION MODEL;

CARDIOVASCULAR DISEASES; HUMANS; MASS SCREENING; MODELS, CARDIOVASCULAR; RISK ASSESSMENT; RISK FACTORS;

EID: 37849032402     PISSN: 01419951     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X260728     Document Type: Conference Paper

References (19)

1. World Health Organization. Cardiovascular disease: prevention and control. World Health Organization 2007 Available at: URL:http://www.who.int/ dietphysicalactivity/publications/ facts/cvd/en/_[Last accessed 19 April 2007]
2. Ohman EM, Bhatt DL, Steg PG, et al. The Reduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events - study design. Am Heart J 2006;151:786.e1-10
3. Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007;297:1253-5
4. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
5. Pyörälä K. Assessment of coronary heart disease risk in populations with different levels of risk. Eur Heart J 2000;21:348-50
6. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998;19:1434-503
7. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003;24:1601-10
8. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53
9. Anderson KM, Wilson PW, Odell PM, et al. An updated coronary risk profile. A statement for health professionals. Circulation 1991;83:356-62
10. D'Agostino RB, Sr, Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001;286:180-7
11. Menotti A, Puddu PE, Lanti M. Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. Eur Heart J 2000;21:365-70
12. Thomsen TF, McGee D, Davidsen M, et al. A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. Int J Epidemiol 2002;31:817-22
13. Hense HW, Schulte H, Lowel H, et al. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany - results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J 2003;24:937-45
14. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003
15. Petersen S, Peto V, Rayner M, et al. European cardiovascular disease statistics. British Heart Foundation Statistics Website 2007 Available at: http://www.heartstats.org/datapage. asp?id=1570 [Last accessed 19 April 2007]
16. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006;113:791-8
17. De Backer G. A total cardiovascular risk estimate should not be used dichotomously. J Hypertens 2006;24:1697-8
18. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39
19. Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91:v1-52